Skip to main content
. 2021 Sep 20;160:105205. doi: 10.1016/j.micpath.2021.105205

Table 3.

Logistic regression analysis of hBD1, hBD2, hBD3 and hBD4 in serum of COVID-19 cases and controls.

hBD Model I

Model II

Model III

OR (95% CI)† p (pc) OR (95% CI)† p (pc) OR (95% CI)† p (pc)
hBD1 1.004 (0.996–1.011) 0.343 (1.0) 1.004 (0.996–1.012) 0.351 (1.0) 1.005 (0.997–1.012) 0.232 (0.928)
hBD2 0.996 (0.993–.998) 0.001 (0.004) 0.996 (0.993–0.998) 0.001 (0.004) 0.996 (0.993–0.998) 0.001 (0.004)
hBD3 0.999 (0.997–1.000) 0.037 (0.148) 0.998 (0.997–1.000) 0.028 (0.112) 0.998 (0.997–1.000) 0.031 (0.124)
hBD4 4.781 (2.579–8.863) < 0.001 (< 0.001) 4.926 (2.627–9.239) < 0.001 (< 0.001) 4.948 (2.632–9.302) < 0.001 (< 0.001)

hBD: Human β-defensin; OR: Odds ratio; CI: Confidence interval; p: Probability; pc: Bonferroni-corrected probability; †: The reference category was controls, and the analysis was adjusted for age (Model I), age and gender (Model II), or age, gender and body mass index (Model III). Significant p-value is bold-marked.